Study Report
Reference
| Citation | Murrough, 2011 PubMed |
| Full Info | Murrough, J.W., Henry, S., Hu, J., Gallezot, J.D., Planeta-Wilson, B., Neumaier, J.F. and Neumeister, A. (2011) Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology (Berl), 213, 547-553.
|
Study
| Hypothesis or Background |
Although serotonin (5-HT) dysregulation is implicated in the pathophysiology of major depressive disorder (MDD), the role of specific receptor subtypes remains to be elucidated. Emerging preclinical research suggests an important role for the 5-HT(1B) receptor in behavioral regulation and depressive phenotypes. In particular, 5-HT(1B) heteroreceptors located within the striatum have been shown to play an essential role in antidepressant action. OBJECTIVES: The objective of this study was to determine 5-HT(1B) receptor binding potential (BP (ND)) in the region of the ventral striatum/ventral pallidum (VS/VP) in individuals with MDD and healthy control participants.
|
| Sample Information | Ten participants with MDD (30.8 +/- 9.5 years, five men/five women) in a current major depressive episode (MDE) and ten healthy control participants (30.7 +/- 10.5 years, five men/five women) |
|---|
| Method Detail | Participants underwent positron emission tomography (PET) scanning with the selective 5-HT(1B) receptor radioligand [(11)C]P943. |
| Method Keywords | positron emission tomography (PET) |
| Result | Within the VS/VP region of interest, [(11)C]P943 BP (ND) was significantly reduced in the MDD group compared with the healthy control group (1.37 +/- 0.13 and 1.68 +/- 0.16, respectively; 18.7% between-group difference; p < 0.001). |
| Conclusions | Consistent with preclinical and postmortem data, our findings suggest abnormally reduced function of VS/VP 5-HT(1B) receptors in humans with MDD. Abnormal 5-HT(1B) heteroreceptor function may contribute to dysfunctional reward signaling within the striatum, including the nucleus accumbens, via interaction with dopamine, gamma-amino-butyric acid, or glutamate systems. Our findings suggest reduced 5-HT(1B) receptor signaling in the VS/VP in MDD and contribute to the therapeutic rationale for testing 5-HT(1B) agonists as a novel class of antidepressants. |
Relationships reported by
Murrough, 2011
| Component A Approved Name (Name in Paper) |
Component A Type |
Component B Approved Name (Name in Paper) |
Component B Type |
Statistical Result |
Relationship Description |
Result Category (Positive/Negative)) |
|
MDD
|
syndrome |
5-hydroxytryptamine receptor 1B (5-HT(1B) receptor) |
protein |
P-value < 0.001 |
Within the ventral striatum/ventral pallidum region of interest, 5-HT(1B) receptor radioligand [(11)C]P943 BP (ND) was significantly reduced in the MDD group compared with the healthy control group (1.37 +/- 0.13 and 1.68 +/- 0.16, respectively; 18.7% between-group difference; p < 0.001). |
Positive
|
|
MDD
|
syndrome |
Ventral striatum (ventral striatum) |
brain morphology and function |
1.37 +/- 0.13 and 1.68 +/- 0.16, respectively; 18.7% between-group difference; P-value < 0.001 |
Within the ventral striatum/ventral pallidum region of interest, 5-HT(1B) receptor radioligand [(11)C]P943 BP (ND) was significantly reduced in the MDD group compared with the healthy control group (1.37 +/- 0.13 and 1.68 +/- 0.16, respectively; 18.7% between-group difference; p < 0.001). |
Positive
|
|
MDD
|
syndrome |
Ventral pallidum (ventral pallidum) |
brain morphology and function |
1.37 +/- 0.13 and 1.68 +/- 0.16, respectively; 18.7% between-group difference; P-value < 0.001 |
Within the ventral striatum/ventral pallidum region of interest, 5-HT(1B) receptor radioligand [(11)C]P943 BP (ND) was significantly reduced in the MDD group compared with the healthy control group (1.37 +/- 0.13 and 1.68 +/- 0.16, respectively; 18.7% between-group difference; p < 0.001). |
Positive
|
